# Mental health disorders among people living with human immunodeficiency virus on antiretroviral therapy in Benin: the overlooked role of sleep quality

**Authors:** Boni Maxime Ale, Calixte Oswald Assogba, Eugénie Dansou, Olushina Ayo Junior Ale, Oswald Lionel Koutangni, Adébiyi Raphaël K Alogou, Simon Giscard Akpi, Kenneth Geovania Dèlonou Damassoh, Eric Youm, Nelly Njeri Wakaba, Houénoudé Mickaël Arnaud Assogba, Kouessi Anthelme Agbodande, Angèle Azon Kouanou, Franck Biaou Guy Ale

PMC · DOI: 10.7189/jogh.16.04076 · Journal of Global Health · 2026-03-06

## TL;DR

This study in Benin finds that poor sleep quality is strongly linked to depression and anxiety in people living with HIV on antiretroviral therapy.

## Contribution

The study highlights the previously overlooked role of sleep quality in mental health outcomes among HIV patients in Benin.

## Key findings

- Depression and anxiety were present in 20.8% and 12.8% of participants, respectively.
- Poor sleep quality was independently associated with higher odds of depression and anxiety.
- Good sleep quality was protective against both mental health disorders.

## Abstract

Depression and anxiety are common comorbidities among people living with HIV (PLHIV) and may be influenced by sleep quality; evidence from Benin remains limited. We assessed the prevalence of depression and anxiety among PLHIV on antiretroviral therapy (ART) and evaluated their association with sleep quality.

We conducted a hospital-based cross-sectional study at Benin’s National Teaching Hospital from December 2023 to February 2024. Adults on ART ≥ 6 months were randomly sampled from the clinic registry. Validated tools were used: Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7, moderate-or-worse threshold ≥ 10; Pittsburgh Sleep Quality Index, poor sleep > 5. Multivariable logistic regression identified factors independently associated with depression and anxiety.

Among 312 participants (68.3% female; mean age 44.3 ± 12.3 years), the prevalence of depression and anxiety was 20.8% (n/N = 65/312) and 12.8% (n/N = 40/312), respectively; poor sleep quality was common (57.1%, n/N = 178/312). Good sleep quality was independently protective for both depression with adjusted odds ratio (aOR) = 0.3, 95% confidence interval (CI) = 0.2–0.6 and anxiety (aOR = 0.4; 95% CI = 0.2–0.9). Age ≥ 44 years was associated with higher odds of anxiety (aOR = 2.1; 95% CI = 1.0–4.5), while other sociodemographic and clinical covariates were not independently associated.

Moderate-or-worse depressive and anxiety symptoms are frequent among PLHIV in this setting, and sleep quality shows a robust independent association with both outcomes. Integrating routine mental-health and sleep screening with clear referral pathways within ART services is warranted; longitudinal and interventional studies should test whether improving sleep reduces symptoms and enhances ART outcomes.

## Linked entities

- **Diseases:** depression (MONDO:0002050), anxiety (MONDO:0005618)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** Sleep impairment (MESH:D012893), pain (MESH:D010146), inflammation (MESH:D007249), neuroinflammation (MESH:D000090862), Anxiety (MESH:D001007), sleep disruption (MESH:D019958), diabetes (MESH:D003920), psychiatric (MESH:D001523), Insomnia (MESH:D007319), overweight (MESH:D050177), noncommunicable diseases (MESH:D000073296), fatigue (MESH:D005221), obese (MESH:D009765), mood (MESH:D019964), anxiety disorders (MESH:D001008), food insecurity (MESH:D005517), mental (MESH:D008607), Hypertension (MESH:D006973), Generalized Anxiety Disorder (MESH:C000726808), ) axis (MESH:C566610), poor (MESH:D009123), Mental health (OMIM:603663), cardiovascular disease (MESH:D002318), Depression (MESH:D003866), PLHIV (MESH:C000719191), underweight (MESH:D013851), neuropathy (MESH:D009422), cognitive disorders (MESH:D003072), HIV (MESH:D015658)
- **Chemicals:** TDF (MESH:D000068698), 3TC (MESH:D019259), DTG (MESH:C562325), EFV (MESH:C098320), AZT (MESH:D015215), DTG - Tenofovir disoproxil fumarate (-), ABC (MESH:C106538), Nevirapine (MESH:D019829), Alcohol (MESH:D000438)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Human immunodeficiency virus 1 (no rank) [taxon 11676], Human immunodeficiency virus (species) [taxon 12721], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12964090/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12964090/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12964090/full.md

---
Source: https://tomesphere.com/paper/PMC12964090